EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Breast Cancer - No.681 Imprimer
Chlebowski et al for the WHI Investigators (JAMA. 2010;304(15):1684-1692. doi:10.1001/jama.2010.1500) reported breast cancer incidence and mortality among participants in the Estrogen Plus Progestin of the WHI trial after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants. In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46; P = .004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs 43 [16.2%], respectively; HR, 1.78; 95% CI, 1.23-2.58; P = .03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96; 95% CI, 1.00-4.04; P = .049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P = .045) among women who received estrogen plus progestin compared with women in the placebo group. (Remark: we have not seen the results from the estrogen only trial).
 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн